MI
ATHE

Motiv8 Investments’s Alterity Therapeutics ATHE Stock Holding History

Motiv8 Investments’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$0 Buy
+40
New +$153 ﹤0.01% 911

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Motiv8 Investments's ATHE Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Alterity Therapeutics (ATHE) in Q4 2025: 40 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #911 among its holdings.

18 funds tracked by Wall St. Rank hold ATHE as of Q4 2025.

  • Motiv8 Investments held 40 shares of Alterity Therapeutics worth $0 as of Q4 2025.
  • Alterity Therapeutics was a new Motiv8 Investments position in Q4 2025.
  • Alterity Therapeutics made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #911 holding.
  • 18 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.